ArticleThe Journal of experimental medicine2002
Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling.
Article in The Journal of experimental medicine, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 99 citations in OpenAlex.
- Immune regulation by erythroid cells: how erythroid progenitor cells and mature red blood cells shape immunity.Nature reviews. Immunology · 2026Review
- SOHO State of the Art Updates and Next Questions | Incorporating Immunotherapy into Upfront Acute Lymphoblastic Leukemia Therapy.Clinical lymphoma, myeloma & leukemia · 2026Review
- The Ligand Binding Domain of the Cell Wall Protein SraP Modulates Macrophage Apoptosis and Inflammatory Responses inMolecules (Basel, Switzerland) · 2025Article
- Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.Cancer · 2024Review
- Role of Siglecs in viral infections: A double-edged sword interaction.Molecular aspects of medicine · 2023Review
- Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation.Journal of biomedical science · 2021Article
- Article
- On the use of abiotic sialic acids to attenuate cell inflammation.Scientific reports · 2018Article
- CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.Frontiers in immunology · 2018Article
- Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- CD22 and CD72 are inhibitory receptors dominantly expressed in B lymphocytes and regulate systemic autoimmune diseases : English version.Zeitschrift fur Rheumatologie · 2017Article
- Modulation of natural killer cell functions by interactions between 2B4 and CD48 in cis and in trans.Open biology · 2016Article
- Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling.The EMBO journal · 2016Article
- [CD22 and CD72 are inhibitory receptors dominantly expressed in B lymphocytes and regulate systemic autoimmune diseases. German version].Zeitschrift fur Rheumatologie · 2016Review
- A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D.PloS one · 2015Article
- Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.Clinical and experimental medicine · 2014Review
- Rethinking mechanisms of autoimmune pathogenesis.Journal of autoimmunity · 2013Review
- B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus.Autoimmune diseases · 2013Review
- CD22 and Siglec-G in B cell function and tolerance.Trends in immunology · 2012Review
- Siglecs and immune regulation.Annual review of immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
CD22, a negative regulator of B cell antigen receptor signaling, binds glycoconjugates terminating in alpha2, 6 sialic acid. The physiological ligand(s) for CD22 remain unknown. We asked whether the sialic acid binding domains are necessary for CD22 to function as a negative regulator. We generated two mutants that lack sialic acid binding activity and expressed them in a novel CD22(-/-) murine B cell line. Anti-IgM activated B cells expressing either CD22 mutant had greater Ca(2+) responses than cells expressing wild-type CD22. Each variant also had reduced CD22 tyrosine phosphorylation and Src homology 2 domain-containing protein tyrosine phosphatase-1 association. These data suggest that the alpha2, 6 sialic acid ligand binding activity of CD22 is critical for its negative regulatory functions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.